Announcements Trials
Browse Landscape

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 68Prostatic Neoplasms 44Leukemia, Myeloid, Acute 35Melanoma 34Lung Neoplasms 28Carcinoma, Non-Small-Cell Lung 28Pancreatic Neoplasms 26Myelodysplastic Syndromes 23Multiple Myeloma 23Colorectal Neoplasms 23Leukemia, Lymphocytic, Chronic, B-Cell 22Neoplasms 21Squamous Cell Carcinoma of Head and Neck 19Neoplasm Metastasis 19Lymphoma, Large B-Cell, Diffuse 19Rectal Neoplasms 16Lymphoma, Mantle-Cell 14Carcinoma, Renal Cell 14Triple Negative Breast Neoplasms 13Stomach Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Colonic Neoplasms 13Lymphoma, Follicular 12Uterine Cervical Neoplasms 11Ovarian Neoplasms 11Leukemia, Myelomonocytic, Chronic 11Head and Neck Neoplasms 11Esophageal Neoplasms 11Myeloproliferative Disorders 10Mouth Neoplasms 9

Interventions

Aprepitant 3desloratadine 1Lidocaine 1Capsules 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pruritus × Biopsy × Clear all
NCT01801670 2015-01-27

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

Boston University

Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Pruritus, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡